Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2102 + TQB2450 + capecitabine
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
TQB2102 + TQB2450 + capecitabine is an investigational combination regimen being developed by Chia Tai Tianqing (part of Sino Biopharmaceutical) for the treatment of HER2-positive advanced gastric or gastroesophageal junction (GEJ) cancer. The triplet regimen consists of three distinct therapeutic agents: TQB2102 (roldimatig deuderuxtecan), a biparatopic HER2-targeted antibody-drug conjugate (ADC) conjugated to a deuterated topoisomerase I inhibitor payload; TQB2450 (benmelstobart), a humanized anti-PD-L1 monoclonal antibody; and capecitabine, an oral fluoropyrimidine chemotherapy prodrug. In a Phase II clinical trial, this combination demonstrated promising antitumor activity as a first-line therapy, achieving an objective response rate (ORR) of 84.2% across the triplet cohorts.
- Other names
- TQB2102 + benmelstobart + capecitabineTQB2102 + TQB2450 + Xelodaroldimatig deuderuxtecan + benmelstobart + Xelodaroldimatig deuderuxtecan + benmelstobart + capecitabine
02
Targets
TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)
Beyond the preview
Go deeper on TQB2102 + TQB2450 + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2102 + TQB2450 + capecitabine.